|
|
Blood, 15 June 2008, Vol. 111, No. 12, pp. 5446-5456.
Prepublished online as a Blood First Edition Paper on January 23, 2008; DOI 10.1182/blood-2007-06-093906.
Previous Article | Table of Contents | Next Article 
REVIEW ARTICLE
This is a new version, updated and corrected, as of December 8, 2008.
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
Michael Hallek1,
Bruce D. Cheson2,
Daniel Catovsky3,
Federico Caligaris-Cappio4,
Guillaume Dighiero5,
Hartmut Döhner6,
Peter Hillmen7,
Michael J. Keating8,
Emili Montserrat9,
Kanti R. Rai10, and
Thomas J. Kipps11
1 Klinik I für Innere Medizin, Universität zu Köln, Köln, Germany;
2 Georgetown University Hospital, Lombardi Cancer Center, Washington, DC;
3 Institute of Cancer Research, London, United Kingdom;
4 Universita Vita-Salute Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele, Milano, Italy;
5 Institute Pasteur, Montevideo, Uruguay;
6 University of Ulm, Ulm, Germany;
7 St James's Institute of Oncology, Leeds, United Kingdom;
8 Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston;
9 Hospital Clinic, IDIBAPS, Barcelona, Spain;
10 Division of Hematology/Oncology, Long Island Jewish Medical Center, New Hyde Park, NY; and
11 Rebecca and John Moores Cancer Center, University of California–San Diego, La Jolla
Standardized criteria for diagnosis and response assessment are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies. Therefore, a National Cancer Institute–sponsored Working Group (NCI-WG) on chronic lymphocytic leukemia (CLL) published guidelines for the design and conduct of clinical trials for patients with CLL in 1988, which were updated in 1996. During the past decade, considerable progress has been achieved in defining new prognostic markers, diagnostic parameters, and treatment options. This prompted the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) to provide updated recommendations for the management of CLL in clinical trials and general practice.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Articles in Blood Online:
-
The proposed diagnostic criteria change for chronic lymphocytic leukemia: unintended consequences?
- Curtis A. Hanson, Paul J. Kurtin, and Ahmet Dogan
Blood 2009 113: 6495-6496.
[Full Text]
[PDF]
-
Lymphocytes, B lymphocytes, and clonal CLL cells: observations on the impact of the new diagnostic criteria in the 2008 Guidelines for Chronic Lymphocytic Leukemia (CLL)
- Christopher S. Mulligan, Miriam E. Thomas, and Stephen P. Mulligan
Blood 2009 113: 6496-6497.
[Full Text]
[PDF]
-
Response: Letters regarding Blood. 2008;111:5446-5456 by Hanson et al and Mulligan et al
- Peter Hillmen, Bruce D. Cheson, Daniel Catovsky, Federico Caligaris-Cappio, Guillaume Dighiero, Hartmut Doehner, Michael J. Keating, Emili Montserrat, Kanti R. Rai, Thomas J. Kipps, and Michael Hallek
Blood 2009 113: 6497-6498.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
A. Dagklis, C. Fazi, C. Sala, V. Cantarelli, C. Scielzo, R. Massacane, D. Toniolo, F. Caligaris-Cappio, K. Stamatopoulos, and P. Ghia
The immunoglobulin gene repertoire of low-count chronic lymphocytic leukemia (CLL)-like monoclonal B lymphocytosis is different from CLL: diagnostic implications for clinical monitoring
Blood,
July 2, 2009;
114(1):
26 - 32.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. G. Nieto, J. Almeida, A. Romero, C. Teodosio, A. Lopez, A. F. Henriques, M. L. Sanchez, M. Jara-Acevedo, A. Rasillo, M. Gonzalez, et al.
Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach
Blood,
July 2, 2009;
114(1):
33 - 37.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Rossi, V. Spina, M. Cerri, S. Rasi, C. Deambrogi, L. De Paoli, L. Laurenti, R. Maffei, F. Forconi, F. Bertoni, et al.
Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome
Clin. Cancer Res.,
July 1, 2009;
15(13):
4415 - 4422.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. A. Hanson, P. J. Kurtin, and A. Dogan
The proposed diagnostic criteria change for chronic lymphocytic leukemia: unintended consequences?
Blood,
June 18, 2009;
113(25):
6495 - 6496.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. S. Mulligan, M. E. Thomas, and S. P. Mulligan
Lymphocytes, B lymphocytes, and clonal CLL cells: observations on the impact of the new diagnostic criteria in the 2008 Guidelines for Chronic Lymphocytic Leukemia (CLL)
Blood,
June 18, 2009;
113(25):
6496 - 6497.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. S Grove, G. A Follows, and W. N Erber
Incidental finding of lymphocytosis in an asymptomatic patient
BMJ,
June 10, 2009;
338(jun10_1):
b2119 - b2119.
[Full Text]
|
 |
|

|
 |

|
 |
 
B. Eichhorst, M. Hallek, M. Dreyling, and On behalf of the ESMO Guidelines Working Group
Chronic lymphocytic leukemia: ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up
Ann. Onc.,
May 1, 2009;
20(suppl_4):
iv102 - iv104.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. E. Marti
The changing definition of CLL
Blood,
April 30, 2009;
113(18):
4130 - 4131.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. D. Shanafelt, N. E. Kay, G. Jenkins, T. G. Call, C. S. Zent, D. F. Jelinek, W. G. Morice, J. Boysen, L. Zakko, S. Schwager, et al.
B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome
Blood,
April 30, 2009;
113(18):
4188 - 4196.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. S. Angelo and R. Kurzrock
Turmeric and Green Tea: A Recipe for the Treatment of B-Chronic Lymphocytic Leukemia
Clin. Cancer Res.,
February 15, 2009;
15(4):
1123 - 1125.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. A. Foon, M. Boyiadzis, S. R. Land, S. Marks, A. Raptis, L. Pietragallo, D. Meisner, A. Laman, M. Sulecki, A. Butchko, et al.
Chemoimmunotherapy With Low-Dose Fludarabine and Cyclophosphamide and High Dose Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
February 1, 2009;
27(4):
498 - 503.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Rossi, M. Cerri, C. Deambrogi, E. Sozzi, S. Cresta, S. Rasi, L. De Paoli, V. Spina, V. Gattei, D. Capello, et al.
The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness
Clin. Cancer Res.,
February 1, 2009;
15(3):
995 - 1004.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Pitini, C. Arrigo, and G. Altavilla
Dasatinib induces a response in chronic lymphocytic leukemia
Blood,
January 8, 2009;
113(2):
498 - 498.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. J. Kipps
Chronic Lymphocytic Leukemia: Advances in Assessing Prognosis and Therapy
ASCO Educational Book,
January 1, 2009;
2009(1):
385 - 393.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. S. Mulligan, M. E. Thomas, and S. P. Mulligan
Monoclonal B-Lymphocytosis: Analysis of the Incidence, Demographics, Nature and Subclassification in 414 Patients
Blood (ASH Annual Meeting Abstracts),
November 16, 2008;
112(11):
3129 - 3129.
[Abstract]
|
 |
|

|
 |

|
 |
 
L. Z. Rassenti, S. Jain, M. J. Keating, W. G. Wierda, M. R. Grever, J. C. Byrd, N. E. Kay, J. R. Brown, J. G. Gribben, D. S. Neuberg, et al.
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia
Blood,
September 1, 2008;
112(5):
1923 - 1930.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. S. Tam, S. O'Brien, W. Wierda, H. Kantarjian, S. Wen, K.-A. Do, D. A. Thomas, J. Cortes, S. Lerner, and M. J. Keating
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
Blood,
August 15, 2008;
112(4):
975 - 980.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Proto-Siqueira, R. A. Panepucci, F. P. Careta, A. Lee, A. Clear, K. Morris, C. Owen, E. G. Rizzatti, W. A. Silva Jr, R. P. Falcao, et al.
SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL
Blood,
July 15, 2008;
112(2):
394 - 397.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|